Human IgG1 Fc Protein

BP4091: In Vivo Grade Recombinant Human IgG1 Fc protein (hIgG1 Fc)

The in vivo grade recombinant human IgG1 Fc protein (hIgG1 Fc, Glu 99 - Lys 330 of the constant region of the IgG1 heavy chain, Accession # P01857-1) was produced in mammalian cells and purified by protein A. The hIgG1 Fc protein includes the CH2 (111-223) and CH3 (224-330) domains of the heavy chain constant region as well as the hinge region (99-110) before the CH2 domain. The C103S version of the hIgG1 Fc protein is also available. The C103S substitution prevents improper cysteine bond formation in the absence of a light chain.
Molecular weight: Predicted 26.1 kDa. Due to glycosylation, the recombinant human IgG1 Fc protein migrates to 32-34 kDa based on the Bis-Tris PAGE result.
Purity: >95% by SDS-PAGE under reducing conditions
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.
Formulation: 0.2 μM filtered solution of 1x PBS.

Shipping: The in vivo grade recombinant human IgG1 Fc protein is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
1 month from date of receipt, 2 to 8°C as supplied.
3 months from date of receipt, -20°C to -70°C as supplied.

Background

The recombinant human IgG1 Fc protein (hIgG1 Fc) includes the CH2 and CH3 domains of the heavy chain constant region. Most of the therapeutic antibody drugs and Fc fusion proteins carry the natural human IgG1 Fc region or engineered mutants. The recombinant human IgG1 Fc protein can be used as the isotype control of the hIgG1 antibodies and the hIgG1 Fc fusion proteins in various in vitro and in vivo experiments.

Changes to the IgG Fc sequence including glycosylation sites have been used to modulate Fc functions. Even a single mutation may have both enhancement and abrogation effects of Fc binding. The following mutations have been introduced to alter the Fc region of an IgG1 antibody or an IgG1 Fc fusion protein to change its immunologic properties by Fc interaction with host proteins:

References of Human IgG1 Fc Protein:

A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice.
Powell, A. E., et al. ACS Cent Sci. 2021 Jan;7(1):183-199. doi: 10.1021/acscentsci.0c01405. PMID: 33527087
For purified mAbs and ACE2-Fc, Direct-Blot HRP antihuman IgG1 Fc antibody was added at a 1:10 000 dilution in diluent buffer for 1 h at room temperature. ...ACE2 binding was measured with Direct-Blot HRP antihuman IgG1 Fc at a 1:10 000 dilution, and blocking was quantified as the decrease in observed ACE2 binding as a function of serum dilution. ...The development of a safe and effective SARS-CoV-2 vaccine is a public health priority. ...Ferritin is an attractive nanoparticle platform for production of vaccines, and ferritin-based vaccines have been investigated in humans in two separate clinical trials. ...Additionally, a single dose of SΔC-Fer elicited significantly higher neutralizing responses as compared to immunization with the spike receptor binding domain (RBD) monomer or spike ectodomain trimer alone.
Tags: Human IgG1 Fc Protein in vivo; Human IgG1 Fc Protein dose

Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy.
Xu, M., et al. EBioMedicine. 2021 Mar;65:103250. doi: 10.1016/j.ebiom.2021.103250. PMID: 33647772
Thereafter, it was transformed to a full-length Fc-silenced anti-PCSK9 antibody FAP2M21 by fusing to a modified human IgG1 Fc fragment with L234A/L235A/N297G mutations and C-terminal lysine deletion, thus eliminating its immune effector functions and mitigating mAb heterogeneity. ...Thereafter, considering the full-length IgG mAb being the most appropriate format for clinical applications because of its long half-life, high stability and bivalent binding property [64,65], we further constructed the full-length Fc-silenced anti-PCSK9 antibodies by fusing two anti-PCSK9 scFv variants (AP2M18 and AP2M21) to a modified human IgG1 Fc fragment with L234A/L235A/N297G mutations and C-terminal lysine deletion, thereby eliminating the immune effector functions and mitigating the potential mAb heterogeneity. ...In summary, we generate a novel, fully human, anti-PCSK9 IgG1 mAb FAP2M21 with a high affinity to PCSK9 and an extremely slow dissociation rate by screening a fully human scFv phage display library, in vitro affinity maturation as well as fusing with a modified human IgG1 Fc fragment. ...Proprotein convertase subtilase/kexin type 9 (PCSK9) regulates serum LDL cholesterol (LDL-C) levels by facilitating the degradation of the LDL receptor (LDLR) and is an attractive therapeutic target for hypercholesterolemia intervention. ...A potent single-chain variable fragment (scFv) named AP2M21 was obtained by screening a fully human scFv phage display library with hPCSK9, and performing two in vitro affinity maturation processes including CDR-targeted tailored mutagenesis and cross-cloning.
Tags: function of Human IgG1 Fc Protein; in vivo study of Human IgG1 Fc Protein

A Novel Splice Variant of Human TGF-β Type II Receptor Encodes a Soluble Protein and Its Fc-Tagged Version Prevents Liver Fibrosis in vivo.
Bertolio, M. S., et al. Front Cell Dev Biol. 2021 Sep;9:690397. doi: 10.3389/fcell.2021.690397. PMID: 34568316
TβRII-SE and human IgG1 Fc domain were fused in frame in a lentiviral vector (Lv) for further characterization. ...Either coTβRII-SE/Fc or TβRII-EC was ligated to the human IgG1 Fc coding sequence and cloned into a self-inactivating (SIN) bicistronic lentiviral vectors making Lv.TβRII-SE/Fc and Lv.TβRII-Fc, respectively. ...The human IgG1 Fc coding sequence was obtained by RT-PCR from peripheral blood leucocyte mRNA using specific oligonucleotides as primers (forward: 5′-AGATCTGACAAAACTCACACATGC-3′ and reverse: 5′-GATATCTTTACCCGGAGACAGG-3′), containing a BglII recognition site (forward primer) and an EcoRV site (reverse primer). ...Transforming growth factor-β (TGF-β) is a multifunctional cytokine involved in critical processes, including immune regulation and wound healing together with cell proliferation, maturation, and differentiation. ...Ligand binding to the receptor ectodomains induces conformational changes at the ligand–receptor interface, bringing their cytoplasmic domains closer.
Tags: Human IgG1 Fc Protein mouse dose range; bulk Human IgG1 Fc Protein

For more references about Human IgG1 Fc Protein please contact our scientific support team with message@sydlabs.com.

hIgG1 Fc R214K (Polatuzumab)
hIgG1 Fc R214K/N297A (Atezolizumab)
hIgG1 Fc L234A/L235A (Risankizumab)
hIgG1 Fc L234F/L235E/P331S (Durvalumab)
hIgG1 Fc L235A/G237A (Vedolizumab)
hIgG1 Fc D356E/L358M (Ocrelizumab)
hIgG1 Fc F126L (Necitumumab)
hIgG1 Fc D265A
hIgG1 Fc F243L/R292P/Y300L/V305I/P396L
hIgG1 Fc S239D/I332E
hIgG1 Fc S239D/I332E/A330L
hIgG1 Fc S298A/E333A/K334A
hIgG1 Fc G236A/S239D/I332E
hIgG1 Fc K326W/E333S
hIgG1 Fc S267E/H268F/S324T
hIgG1 Fc E345R/E430G/S440Y
hIgG1 Fc N297A
hIgG1 Fc N297Q
hIgG1 Fc N297G
hIgG1 Fc L235E
hIgG1 Fc L234A/L235A
hIgG1 Fc M252Y/S254T/T256E
hIgG1 Fc M428L/N434S
hIgG1 Fc S267E/L328F
hIgG1 Fc N325S/L328F

Recombinant natural and engineered human IgG1 Fc proteins, and recombinant human IgG1 isotype control antibody and mutants are available. Biotinylated hIgG1 Fc, and hIgG1 Fc with Avi-, His-, and DYKDDDDK-tags are also available. Please contact us to ask for a quote for the engineered human IgG1 Fc proteins, biotinylated hIgG1 Fc, and hIgG1 Fc with Avi-, His-, and DYKDDDDK-tags.

Other Recombinant IgG Fc Proteins:
In vivo Grade Recombinant Human IgG1 Fc Protein (hIgG1)
In vivo Grade Recombinant Human IgG2 Fc Protein (hIgG2)
In vivo Grade Recombinant Human IgG4 Fc Protein (hIgG4)
In vivo Grade Recombinant Mouse IgG1 Fc Protein (mIgG1)
In vivo Grade Recombinant Mouse IgG2a Fc Protein (mIgG2a)
In vivo Grade Recombinant Mouse IgG2b Fc Protein (mIgG2b)
In vivo Grade Recombinant Mouse IgG2c Fc Protein (mIgG2c)
In vivo Grade Recombinant Mouse IgG3 Fc Protein (mIgG3)
In vivo Grade Recombinant Rat IgG2a Fc Protein (rtIgG2a)
In vivo Grade Recombinant Rat IgG2b Fc Protein (rtIgG2b)
In vivo Grade Recombinant Llama IgG2b Fc Protein (lIgG2b)
In vivo Grade Recombinant Rabbit IgG Fc Protein (rIgG)

Recombinant IgG Reference Antibodies:
In vivo Grade Recombinant Human IgG1 Isotype Control Antibody and Mutants
In vivo Grade Recombinant Human IgG2 Isotype Control Antibody
In vivo Grade Recombinant Human IgG3 Isotype Control Antibody
In vivo Grade Recombinant Human IgG4-S228P Isotype Control Antibody and Mutants
In vivo Grade Recombinant Mouse IgG1 Isotype Control Antibody and Mutants
In vivo Grade Recombinant Mouse IgG2a Isotype Control Antibody and Mutants
In vivo Grade Recombinant Mouse IgG2b Isotype Control Antibody and Mutants
In vivo Grade Recombinant Mouse IgG2c Isotype Control Antibody and Mutants
In vivo Grade Recombinant Mouse IgG3 Isotype Control Antibody
In vivo Grade Recombinant Rat IgG1 Isotype Control Antibody
In vivo Grade Recombinant Rat IgG2a Isotype Control Antibody
In vivo Grade Recombinant Rat IgG2b Isotype Control Antibody
In vivo Grade Recombinant Rat IgG2c Isotype Control Antibody

Fc ELISA Kits and Reagents:
Human Fc ELISA Kit
Mouse Fc ELISA Kit
Human Fc ELISA Reagent Kit
Mouse Fc ELISA Reagent Kit

Protein A, Resin, Columns, and ELISA Kits:
Recombinant Protein A
Protein A Affinity Resin
Pre-packed Protein A Column
Protein A ELISA Kit